Send to

Choose Destination
Int J Biol Sci. 2018 Oct 19;14(13):1791-1799. doi: 10.7150/ijbs.25352. eCollection 2018.

miR-186-5p Promotes Apoptosis by Targeting IGF-1 in SH-SY5Y OGD/R Model.

Author information

Department of Neurology, the Second Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang Province, 150001, China.
Department of Neurosurgery, Harbin Medical University Cancer Hospital, Harbin, Heilongjiang Province, 150001, China.
Department of Neurosurgery, First Affiliated Hospital of Jiamusi University, Jiamusi, Heilongjiang Province, 154002, China.
Department of Neurosurgery, the Second Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang Province, 150001, China.
Department of Neurology, First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan Province, 450000, China.


In recent years, accumulating evidence has revealed that microRNAs play critical roles in ischemia stroke. This study was designed to investigate the expression level and effects of microRNA (miR)-186-5p on ischemia stroke, and its underlying molecular mechanism. Firstly, we demonstrated that miR-186-5p were significantly up-regulated and induced apoptosis in oxygen and glucose deprivation/reperfusion (OGD/R) model. Moreover, we found that miR-186-5p reduced the expression of insulin-like growth factor (IGF)-1, an essential factor for the development of the nervous system. Meanwhile, miR-186-5p inhibitor enhanced cell viability and IGF-1 expression. Furthermore, IGF-1 was confirmed as a direct target gene of miR-186-5p by luciferase activity assay. In addition, miR-186-5p was upregulated in ischemia stroke patients' serum compared with healthy donors. These data demonstrated that miR-186-5p was an adverse factor by inducing neuron apoptosis and suppressing IGF-1 in ischemia stroke model, and suggested that miR-186-5p may be a diagnostic marker and potential therapeutic target for ischemia stroke patients.


IGF-1; apoptosis; ischemia stroke; miR-186-5p

Conflict of interest statement

Competing Interests: The authors have declared that no competing interest exists.

Supplemental Content

Full text links

Icon for Ivyspring International Publisher Icon for PubMed Central
Loading ...
Support Center